Augmenting Response to Entecavir With Peginterferon a-2a for the Treatment of HBeAg-positive Chronic Hepatitis B

PHASE4CompletedINTERVENTIONAL
Enrollment

184

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Chronic Hepatitis B
Interventions
DRUG

pegylated interferon a-2a

180 μg, once per week s.c. for 24 weeks

DRUG

Entecavir

0.5 mg once daily per os, either 72 weeks or 96 weeks

Trial Locations (13)

Unknown

Ruijin Hospital, Shanghai

Shanghai Public Health Center, Shanghai

Zhong Shan hospital, Fu Dan University, Shanghai

Amsterdam Medical Center (AMC), Amsterdam

Erasmus Medical Center, Rotterdam

CMUMU, Bydgoszcz

Medical University, Dept of Infections Diseases, Wroclaw

WAMED, Zawiercie

Fundeni Clinical Institute, Bucharest

Nat. Institute of inf. Disease, Bucharest

University of Ankara, Medical School, Ankara

Yuksek Ihsitas Hospital, Dept. Gastroenterology, Ankara

Cerrahpasa Medical Faculty, Istanbul

Sponsors
All Listed Sponsors
lead

Foundation for Liver Research

OTHER